COMP <GO>
CBT vs VVV // EV/EBITDA & P/E VALUATION
Cabot Corporation (NYSE) VS. Valvoline Inc. (NYSE) • 15-METRIC TALLY: CBT 6
— VVV 6
▲ EV/EBITDA & P/E VALUATION LEADER: CBT
LAST: $74.43 (+0.79%) • MKT CAP: $3.81B
valuation
5.2x
LAST: $32.29 (-0.28%) • MKT CAP: $4.13B
valuation
9.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CBT VS. VVV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CBT | VVV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 25.30% | 38.50% | -13.20 | VVV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 22.30% | 16.50% | +5.80 | CBT | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 5.2x | 9.3x | -4.10 | CBT | /valuation <GO> |
| Free Cash Flow Yield | 10.25% | 0.92% | +9.33 | CBT | /fcf-yield <GO> |
| Operating Margin | 16.70% | 22.80% | -6.10 | VVV | /operating-margins <GO> |
| Net Profit Margin | 8.90% | 12.30% | -3.40 | VVV | /net-margins <GO> |
| Revenue Growth (YoY) | -7.00% | 5.60% | -12.60 | VVV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.52% | 0.00% | +2.52 | CBT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 2.46 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 6/9 | +1.00 | CBT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.6 | 59.6 | -19.00 | VVV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.98 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.7x | 18.2x | -7.50 | CBT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.81B | $4.13B | -$318.3M | VVV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CBT REV | VVV REV | CBT GROSS % | VVV GROSS % | CBT FCF | VVV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.71B | $1.71B | 25.3% | 38.5% | $391.0M | $38.0M |
| FY 2024 | $3.99B | $1.62B | 24.0% | 38.2% | $451.0M | $40.7M |
| FY 2023 | $3.93B | $1.44B | — | — | $595.0M | -$105.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CBT // BETA —
VVV // BETA 0.98